Posters/Publications

oral

Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial

EASL International Liver Congress

Date - 06/2023

paper

Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

Clinical Cancer Research

Date - 04/2023

poster

Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development

HCC-TAG

Date - 02/2023

poster

Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies

NASH-TAG

Date - 01/2023

poster

Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients

NASH-TAG

Date - 01/2023

oral

Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH

AASLD The Liver Meeting

Date - 11/2022

poster

A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies

AASLD The Liver Meeting

Date - 11/2022

poster

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

AASLD The Liver Meeting

Date - 11/2022

paper

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Scientific Reports

Date - 09/2022

paper

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

Nature Communications

Date - 07/2022

Posters/Publications

Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial

Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development

Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies

Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients

Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH

A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

Site map

Contact us